Voyager Biomedical

Voyager develops vascular access solutions for dialysis patients. Its flagship product, VenaSure, aims to provide standardized cannulation methods intended to improve patient comfort, reduce complications, and streamline dialysis procedures.

VenaSure provides a palpable target for AV fistula access. Its porous, lightweight titanium design integrates with tissue to support the vein.

The website collects comment-form data, visitors’ IP addresses, and browser user-agent strings to help detect spam.

Voyager Biomedical CEO Marc Penna discusses strategies for assessing early-stage medtech opportunities. He highlights methods to reduce regulatory risks and align fundraising timelines with development milestones. Penna draws on his experience navigating challenges in medical device innovation.

Sep 2025SNLNews article

Isomorphic Labs secures **GBP 449 million** in venture funding, led by **Thrive Capital**, with participation from **GV (Alphabet)** and other undisclosed investors. The round values the company at **GBP 942 million** pre-money. The funding follows a deal announced on **March 31, 2025**, though the company’s focus area remains unspecified in the report.

Apr 2025Silverwood PartnersNews article

Texas A&M researchers collaborate to develop **Ark**, a breakthrough device for chronic kidney disease patients. The technology aims to extend dialysis treatment duration and enhance patient outcomes. The innovation builds on ongoing research to address critical gaps in kidney care.

May 2024Texas A&M StoriesNews article